Atazanavir + Ritonavir + ABC-3TC

SHARE Trial

Atazanavir + Ritonavir + ABC-3TC in Treatment-Naïve
SHARE: Study Design

Study Design: SHARE

- **Background**: Nonrandomized, open-label, single-arm pilot study evaluating the efficacy and safety of once-daily abacavir-lamivudine plus ritonavir-boosted atazanavir in treatment-naïve adults with HIV infection
- **Inclusion Criteria (n = 112)**
  - Age ≥18
  - Antiretroviral treatment-naïve
  - HIV RNA ≥5000 copies/mL
  - No AIDS-defining illnesses in previous 30 days
- **Treatment Arms** (All Once daily)
  - Atazanavir 300 mg + Ritonavir 100 mg + Abacavir-Lamivudine 600/300 mg

→

Atazanavir + ritonavir + ABC-3TC
(n = 111)

Source: Elion R, et al. HIV Clin Trials. 2008;9:152-63.

Atazanavir + Ritonavir + ABC-3TC in Treatment-Naïve
SHARE: Results

Week 48: Virologic Response, by Baseline HIV RNA (ITT, M=F)



Source: Elion R, et al. HIV Clin Trials. 2008;9:152-63.

National HIV Curriculum

Atazanavir + Ritonavir + ABC-3TC in Treatment-Naïve

SHARE: Results

Week 48: Change in Fasting Lipids from Baseline



Source: Elion R, et al. HIV Clin Trials. 2008;9:152-63.

Atazanavir/r + ABC-3TC in Treatment-Naïve
SHARE: Conclusions

Conclusion: "ABC/3TC and ATV-RTV QD is an effective and well-tolerated regimen in ART-naïve patients through 48 weeks, with a modest impact on fasting lipids."

Source: Elion R, et al. HIV Clin Trials. 2008;9:152-63.

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

National HIV Curriculum

AETC AIDS Education & Training Center Program
National Coordinating Resource Center